Troy A. Ignelzi Purchases 9,900 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics (NASDAQ:RAPPGet Free Report) CFO Troy A. Ignelzi acquired 9,900 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were acquired at an average cost of $10.10 per share, with a total value of $99,990.00. Following the transaction, the chief financial officer now owns 9,900 shares in the company, valued at approximately $99,990. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Rapport Therapeutics Stock Up 4.9 %

Shares of Rapport Therapeutics stock opened at $10.51 on Friday. The stock’s fifty day moving average is $13.54 and its 200 day moving average is $18.74. Rapport Therapeutics has a one year low of $6.43 and a one year high of $29.74.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RAPP. Deutsche Bank AG purchased a new stake in Rapport Therapeutics in the 4th quarter worth approximately $41,000. Crestline Management LP purchased a new stake in shares of Rapport Therapeutics in the fourth quarter worth $488,000. Virtus ETF Advisers LLC bought a new stake in shares of Rapport Therapeutics during the 4th quarter valued at $66,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Rapport Therapeutics by 9.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock valued at $20,285,000 after buying an additional 95,976 shares in the last quarter. Finally, TRV GP V LLC bought a new position in Rapport Therapeutics in the 4th quarter worth $126,579,000.

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.

See Also

Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.